PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 22:12 (1690 d 23:57 ago) – Posting: # 21915
Views: 4,175

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
95 visitors (0 registered, 95 guests [including 3 identified bots]).
Forum time: 22:09 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5